SG11202107643YA - Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis b - Google Patents
Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis bInfo
- Publication number
- SG11202107643YA SG11202107643YA SG11202107643YA SG11202107643YA SG11202107643YA SG 11202107643Y A SG11202107643Y A SG 11202107643YA SG 11202107643Y A SG11202107643Y A SG 11202107643YA SG 11202107643Y A SG11202107643Y A SG 11202107643YA SG 11202107643Y A SG11202107643Y A SG 11202107643YA
- Authority
- SG
- Singapore
- Prior art keywords
- amide
- sulphiamidine
- treating hepatitis
- aryl
- internal cyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910027573.6A CN111434665B (en) | 2019-01-11 | 2019-01-11 | Ensultamidenamide-arylamide compounds and their use for treating hepatitis B |
| PCT/CN2020/071523 WO2020143798A1 (en) | 2019-01-11 | 2020-01-10 | Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107643YA true SG11202107643YA (en) | 2021-08-30 |
Family
ID=71520539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107643YA SG11202107643YA (en) | 2019-01-11 | 2020-01-10 | Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis b |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220380384A1 (en) |
| EP (1) | EP3909957A4 (en) |
| JP (1) | JP2022517984A (en) |
| KR (1) | KR102650441B1 (en) |
| CN (2) | CN111434665B (en) |
| AU (1) | AU2020205923B2 (en) |
| BR (1) | BR112021013730A2 (en) |
| CA (1) | CA3126570A1 (en) |
| MX (1) | MX2021008386A (en) |
| SG (1) | SG11202107643YA (en) |
| WO (1) | WO2020143798A1 (en) |
| ZA (1) | ZA202105438B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115160344A (en) * | 2021-04-06 | 2022-10-11 | 上海长森药业有限公司 | Inhibition of CD4 by oral administration + Medicaments and methods for Treg cells |
| CN115177624A (en) * | 2021-04-06 | 2022-10-14 | 上海长森药业有限公司 | Method for treating HBV by increasing viral empty capsid protein through oral administration |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166157B (en) | 2011-07-01 | 2019-08-02 | 巴鲁·S·布隆伯格研究所 | As the sulfonamides heterocyclic carbamate derivatives for preventing hepatitis b virus infected antivirotic |
| TWI622578B (en) | 2011-12-21 | 2018-05-01 | 諾維拉治療公司 | Hepatitis b antiviral agents |
| CN105980378B (en) * | 2014-02-06 | 2019-09-27 | 爱尔兰詹森科学公司 | Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug |
| AU2015243585B2 (en) * | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US10875876B2 (en) * | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108250121A (en) * | 2016-12-28 | 2018-07-06 | 上海长森药业有限公司 | Sulfonamide-arylamides and its medicinal usage for treating hepatitis B |
| CN108264520B (en) * | 2017-01-03 | 2021-12-07 | 上海长森药业有限公司 | Compound for treating hepatitis B and application thereof |
| WO2018133846A1 (en) * | 2017-01-23 | 2018-07-26 | 上海长森药业有限公司 | Cyclothiourea compound and use thereof |
| WO2018153326A1 (en) * | 2017-02-22 | 2018-08-30 | 上海长森药业有限公司 | Sulfonyl hydrazine compound and use thereof |
| CN109251158B (en) * | 2017-07-14 | 2023-05-23 | 上海长森药业有限公司 | Thioamidine amide compounds and use thereof for treating hepatitis B |
| CN109251212A (en) * | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B |
-
2019
- 2019-01-11 CN CN201910027573.6A patent/CN111434665B/en active Active
-
2020
- 2020-01-10 SG SG11202107643YA patent/SG11202107643YA/en unknown
- 2020-01-10 MX MX2021008386A patent/MX2021008386A/en unknown
- 2020-01-10 BR BR112021013730-0A patent/BR112021013730A2/en unknown
- 2020-01-10 AU AU2020205923A patent/AU2020205923B2/en active Active
- 2020-01-10 JP JP2021540294A patent/JP2022517984A/en active Pending
- 2020-01-10 CA CA3126570A patent/CA3126570A1/en active Pending
- 2020-01-10 KR KR1020217025454A patent/KR102650441B1/en active IP Right Grant
- 2020-01-10 EP EP20738690.5A patent/EP3909957A4/en active Pending
- 2020-01-10 US US17/421,819 patent/US20220380384A1/en active Pending
- 2020-01-10 WO PCT/CN2020/071523 patent/WO2020143798A1/en unknown
- 2020-01-10 CN CN202080008964.4A patent/CN113286798B/en active Active
-
2021
- 2021-07-30 ZA ZA2021/05438A patent/ZA202105438B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022517984A (en) | 2022-03-11 |
| MX2021008386A (en) | 2021-11-17 |
| BR112021013730A2 (en) | 2021-09-21 |
| US20220380384A1 (en) | 2022-12-01 |
| CN111434665A (en) | 2020-07-21 |
| KR20210134621A (en) | 2021-11-10 |
| EP3909957A4 (en) | 2022-09-07 |
| CA3126570A1 (en) | 2020-07-16 |
| WO2020143798A1 (en) | 2020-07-16 |
| CN111434665B (en) | 2023-03-10 |
| ZA202105438B (en) | 2022-09-28 |
| CN113286798B (en) | 2022-08-02 |
| CN113286798A (en) | 2021-08-20 |
| EP3909957A1 (en) | 2021-11-17 |
| KR102650441B1 (en) | 2024-03-21 |
| AU2020205923B2 (en) | 2022-12-01 |
| AU2020205923A1 (en) | 2021-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263558A (en) | Papd5 and papd7 inhibitors for treating a hepatitis b infection | |
| EP3653630A4 (en) | Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis b | |
| IL283525A (en) | Cyclic pantetheine derivatives and uses thereof | |
| IL274040A (en) | Methods for treating hepatitis b infection | |
| ZA202106304B (en) | Heterocyclic compound and use thereof | |
| ZA202105438B (en) | Internal cyclic sulphiamidine amide-aryl amide compound and use thereof for treating hepatitis b | |
| IL284116A (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections | |
| PT3656782T (en) | Peptide amide compound and preparation method and medical use thereof | |
| SG11202006916SA (en) | Nitrogenated heterocyclic amide compound, and use thereof for medical purposes | |
| IL288082A (en) | Amide compounds and preparation method therefor and use thereof | |
| EP4006024A4 (en) | Heterocyclic amide compound, preparation method therefor and use thereof | |
| LT3416675T (en) | Treatment of hepatitis delta virus infection with interferon lambda | |
| EP3965832A4 (en) | Compositions and methods for treating hepatitis b | |
| GB2576890B (en) | Heating of an exhaust after-treatment component | |
| IL276912A (en) | Heterocyclic compound and use thereof | |
| IL267937A (en) | Amide compounds and use thereof | |
| SG11202011170YA (en) | Antibodies against lif and dosage forms thereof | |
| EP4069369A4 (en) | Cyclic compounds and methods of using same | |
| SG11202000347UA (en) | A composition for treating and/or preventing hepatitis b virus infection and the use thereof | |
| EP3978076A4 (en) | Cyclic amide compounds for rabies treatment and method thereof | |
| IL279441A (en) | N-substituted tetrahydrothienopyridine derivatives and uses thereof | |
| GB202204938D0 (en) | Compounds comprising curcmin and basic amino acids | |
| GB201916573D0 (en) | Formula and process | |
| EP4126844A4 (en) | Amide compounds and uses thereof | |
| IL275991A (en) | Cyclic amine derivative and medical use thereof |